When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ADAP - Adaptimmune Is A Good Speculative Biotech But More Confirmation Is Needed From Next Study
Adaptimmune Therapeutics plc
Adaptimmune Therapeutics (ADAP) is a good speculative biotech to look into in considering to add to the portfolio. That's because it announced some preliminary positive data in patients with synovial sarcoma. On the flip side, the data was only achieved in a phase 1 study. There is a currently ongoing phase 2 study but it could be some time before data from that study is known. Still, if this biotech can pull off T-cell Receptor Therapy ((TCR)) in solid tumors, it could achieve significant value in the long run. That's because cell